UK News
-
Cancer-detection apps don’t identify life-threatening diseases
A direct-to-consumer machine learning model for detecting skin cancers available on app stores incorrectly classified rare and aggressive cancers as low-risk, a conference has heard. Read more
-
Taking long-term antidepressants reduces relapse risk
Many users of antidepressants experience a relapse within a year if they stop taking the medication, a new study reveals. Read more
-
Lack of evidence for HRT-dementia risk
There is no strong link between hormone replacement therapy and dementia, according to the findings of a major UK study published today. Read more
-
High rates of long COVID diagnosis
More than a third of patients diagnosed with COVID-19 develop at least one persistent symptom of long COVID, according to a new analysis. Read more
-
Poorer children less likely to want the COVID-19 vaccine
Children from the most socioeconomically deprived backgrounds are more likely than others to say they do not want to have the COVID-19 vaccine, researchers report today. Read more
-
Healthy diet linked to child mental health
Children who have a healthy diet, with plenty of fruit and vegetables, may benefit from improved mental wellbeing, a new study has shown. Read more
-
Smoking ‘worsens COVID-19 severity’ and risk of death
Smoking is highly likely to worsen the severity of COVID-19 and the risk of dying from the virus, researchers report today in a study aimed at dispelling another pandemic myth. Read more
-
AI identifies possible drug combination for brain cancer
Artificial intelligence-enhanced tools have been used to identify a new combination of drugs that could treat a rare and incurable childhood brain cancer. Read more
-
Parent-led intervention for early signs of autism
Early parent-led intervention may help infants with autism spectrum disorder-related behaviours manage their symptoms, according to a major new study. Read more
-
First multi-variant COVID-19 vaccine trial starts
The world’s first multi-variant COVID-19 booster vaccine is to undergo phase 1 trials among older adults in Manchester. Read more
